We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI Platform Identifies 99% of Positive Cancer Cases in Pathology Reports

By LabMedica International staff writers
Posted on 14 Mar 2022

For most people, the shock of a cancer diagnosis quickly gives way to an action plan — disease research, doctor appointments, treatment options, and support outlets. More...

But many patients are not able to take these steps or advocate for themselves. Some simply don't know how to move forward, which results in more complicated and expensive care, reduced life expectancies, and inferior health outcomes. A new artificial intelligence (AI) platform disrupts the manual and repetitive processes in healthcare to identify positive cancer diagnosis and incidental findings in real time, classify those diagnoses by primary site, and route those patients to cancer navigators and other staff to immediately start the cancer care journey.

The results of this new platform from Azra AI (Franklin, TN, USA) include faster time to treatment, increased navigator time with patients, and better patient retention in a health system's oncology program. In addition, Azra AI's platform improves healthcare operations with dramatic operational and financial gains through automation. More specifically, this new technology decreased time from diagnosis-to-treatment by seven days across all cancer types, improved patient retention by 75% and increased revenues over 10% in the first 14 months of use.

Azra AI's technology is making a tremendous impact in the oncology realm and has saved countless hours for hospital staff by combing through CT scan results with exceptional speed and accuracy. Healthcare leaders have also found that the Azra AI platform performs better than manual processes and completes reviews much faster. A recent analysis of one health system's records using the Azra AI platform found that the technology identified 99% of positive cancer cases in pathology reports that had previously been manually reviewed by healthcare staff.

"We are already helping thousands of cancer patients and clinicians everyday with our AI-enhanced intelligent workflows," said Azra AI CEO Chris Cashwell. "With the crisis in nurse staffing and uncertainty of post-COVID cancer patient volumes, our technology can be a lifeline to clinicians and a life saver for patients. From finding incidental lung nodules to reducing time to treatment, providers are having a profound impact using our technology."

Related Links:
Azra AI 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.